Invesco Biotechnology & Genome ETF
Invesco Biotechnology & Genome ETF (PBE) Historical Volatility
PBE's 30 day historical volatility is 27.68%, in the 96th percentile of readings over the past year. This is a high percentile, meaning Invesco Biotechnology & Genome ETF shares have swung far more than usual. PBE's 30 day implied volatility sits at 31.35%, with an IV Rank of 97.22%, leaving IV 3.67 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 20, 2026.
Read more
Tracking PBE historical volatility helps you see how much Invesco Biotechnology & Genome ETF's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, PBE's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor PBE 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. PBE's 30 day historical volatility, or PBE HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing PBE's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 20, 2026
As of Nov 20, 2026
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →